Drug intelligence / Profile preview

TRI102

Development stage: Unknown
Lead developer: TRACON Pharmaceuticals
Administration: Oral

Overview

TRI102 is an investigational pharmaceutical drug currently in Phase 3 clinical trials for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6-12. The drug is administered once daily. The Phase 3 study is designed as a randomized, double-blind, placebo-controlled, parallel-group, multicenter, laboratory classroom study to evaluate its effectiveness.

Targets

TYMP (Thymidine phosphorylase)DNA

Beyond the preview

Go deeper on TRI102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRI102.

Explore the full profile